NEXSPIKE is Moderna’s third product to receive a positive CHMP opinion alongside Spikevax (COVID-19 Vaccine, mRNA) and ...
NEXSPIKE is Moderna's third product to receive a positive CHMP opinion alongside Spikevax (COVID-19 Vaccine, mRNA) and mRESVIA (Respiratory Syncytial Virus Vaccine)mNEXSPIKE will be available in the E ...
Merck secures a positive CHMP opinion to expand Winrevair's PAH use, potentially broadening treatment to adult patients ...
Mumbai: Global pharma major Lupin Limited has announced that the Committee for Medicinal Products for Human Use (CHMP) of the ...
EMA committee recommends marketing approval for Lupin’s biosimilar ranibizumab: Our Bureau, Mumbai Wednesday, December 17, 2025, 14:40 Hrs [IST] Global pharma major Lupin Limite ...
Lupin said the Committee for Medicinal Products for Human Use (CHMP) has backed the approval of the biosimilar, to be ...
The European regulator has recommended marketing approval for Ranluspec and Gotenfia after studies confirm their safety, ...
Phase 3 studies point to sustained disease control in patients who remain symptomatic despite standard therapies.
GSK’s depemokimab, a long-acting biologic that’s key in the British pharma’s growth plan, has won an endorsement from ...
Moderna on Monday said that the European Medicines Agency's Committee for Medicinal Products for Human Use recommended the marketing authorization of mNexspike, a new Covid-19 vaccine. The committee's ...
Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) recommended the ...
Final Decision from European Commission Expected in Q1 2026SOUTH SAN FRANCISCO, Calif., (GLOBE NEWSWIRE) -- Cytokinetics, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results